Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Participants who (or whose parent/legal representative) are able to give written informed consent.~* Participants must be 10 years of age or older and 17 years of age or younger at the time of treatment assignment (randomization).~* Participants must have a diagnosis of bipolar I disorder, confirmed by structured interview at screening.~* Participants must not be pregnant or lactating, and those who are sexually active or become sexually active during the trial, and of child-bearing potential, must be using a medically accepted form of birth control.~* Participants will be required to have stopped taking certain psycho-active medications prior to baseline.~* Participants must have a caregiver, or other responsible person living with them who agrees to provide support to the participant to ensure study and procedure compliance.~Exclusion criteria:~* Diagnosis of bipolar II disorder, or other form of bipolar or psychotic disorder.~* Known or suspected mental retardation.~* Substance abuse, or dependence, within the past 6 months.~* There is risk of self-harm or harm to others.~* There is a history of tardive dyskinesia or dystonia.~* Pregnancy or lactation during the study.~* History of seizure disorder.~* Participation in any other clinical trial at the same time.~* A family member who is part of the study staff or is directly involved with the study.~* Other medical conditions determined by the study staff to possibly interfere with the study safety and efficacy evaluations.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Asenapine 2.5 mg twice daily (BID) (Type: EXPERIMENTAL): Participants receive asenapine 2.5 mg BID for 21 days.
- Asenapine 5.0 mg BID (Type: EXPERIMENTAL): Participants receive asenapine 2.5 mg BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive asenapine 5.0 mg BID for the remainder of the 21-day treatment period.
- Asenapine 10.0 mg BID (Type: EXPERIMENTAL): Participants receive asenapine 2.5 mg BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. On Day 5 and 6 participants receive asenapine 5.0 mg BID. On Day 7 participants receive asenapine 5.0 mg in the morning and 10.0 mg in the evening. Participants receive asenapine 10.0 mg BID for the remainder of the 21-day treatment period.
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive placebo BID for 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).